Michael Amoroso Sells 36,838 Shares of Precision BioSciences, Inc. (NASDAQ:DTIL) Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) CEO Michael Amoroso sold 36,838 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $4.67, for a total value of $172,033.46. Following the completion of the transaction, the chief executive officer now owns 107,087 shares of the company’s stock, valued at $500,096.29. This represents a 25.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Michael Amoroso also recently made the following trade(s):

• On Monday, November 4th, Michael Amoroso sold 3,012 shares of Precision BioSciences stock. The shares were sold at an average price of $8.19, for a total value of $24,668.28.

Precision BioSciences Trading Up 0.6 %

NASDAQ DTIL opened at $5.00 on Friday. The stock has a market capitalization of $38.35 million, a price-to-earnings ratio of 83.35 and a beta of 1.51. The stock’s 50 day moving average price is $5.56 and its two-hundred day moving average price is $8.01. The company has a debt-to-equity ratio of 0.34, a quick ratio of 9.22 and a current ratio of 9.22. Precision BioSciences, Inc. has a 52 week low of $3.61 and a 52 week high of $19.43.

Institutional Investors Weigh In On Precision BioSciences

An institutional investor recently raised its position in Precision BioSciences stock. Geode Capital Management LLC lifted its stake in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) by 40.7% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 65,974 shares of the company’s stock after purchasing an additional 19,088 shares during the period. Geode Capital Management LLC owned 0.86% of Precision BioSciences worth $591,000 at the end of the most recent quarter. Institutional investors own 37.99% of the company’s stock.

Wall Street Analyst Weigh In

DTIL has been the subject of several research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of Precision BioSciences in a research report on Friday, January 10th. BMO Capital Markets upgraded Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 target price on the stock in a research note on Friday, January 10th.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.